Online First 2023-06-30

Introduction: Recently, a stratification of the heart failure (HF) phenotypes, which classifies HF into 3 subtypes based on ejection fraction, has been introduced. Before that, clinical trials and registries have been mainly devoted to HF with reduced ejection fraction (HFrEF). As a result, data on long-term survival trends for individual HF phenotypes are scarce. Objectives: The study aimed to evaluate survival according to the HF phenotype and to identify predictors of mortality. Patients and methods: Patients hospitalized for HF in our referral center between January 2014 and May 2019 were included in the analysis. HF phenotyping was based on EF: reduced (HFrEF with EF <⁠40%), mildly reduced (HFmrEF with EF = 40%–49%), and preserved (HFpEF with EF ≥50%). Results: Of 2601 patients included in the study, 1608 individuals (62%) presented with HFrEF, 331 patients with HFmrEF (13%), and 662 patients with HFpEF (25%). The median follow-up was 2.43 years (interquartile range, 1.56–3.49). The risk of death was 61% higher in HFrEF than in HFpEF (P <⁠0.001), while in HFmrEF and HFpEF it was similar. Survival rates at 1 and 5 years in HFrEF, HFmrEF, and HFpEF were 81%, 84%, 84%, and 47%, 61%, and 59%, respectively. The HF phenotypes differed in most of the parameters that affect prognosis. Only the use of inotropes, which was linked to an increased risk of death, and the use of angiotensin-converting enzyme inhibitors, which reduced this risk, were independent of the HF phenotype. Conclusions: Survival in HFrEF is worse as compared with HFmrEF and HFpEF, where it is similar. The HF phenotypes differ in most of the parameters that affect survival.